"Ceftazidime" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
| Descriptor ID |
D002442
|
| MeSH Number(s) |
D02.065.589.099.249.210.150 D02.886.665.074.210.150 D03.633.100.300.249.210.150
|
| Concept/Terms |
Ceftazidime- Ceftazidime
- Ceftazidime Pentahydrate
- Pentahydrate, Ceftazidime
|
Below are MeSH descriptors whose meaning is more general than "Ceftazidime".
Below are MeSH descriptors whose meaning is more specific than "Ceftazidime".
This graph shows the total number of publications written about "Ceftazidime" by people in this website by year, and whether "Ceftazidime" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2017 | 16 | 10 | 26 |
| 2018 | 19 | 7 | 26 |
| 2019 | 6 | 2 | 8 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ceftazidime" by people in Profiles.
-
Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Signal Transduct Target Ther. 2021 05 18; 6(1):198.
-
Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARSCoV-2 Nosocomial Infection. Medicina (Kaunas). 2021 Apr 28; 57(5).
-
The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome. J Med Virol. 2020 10; 92(10):2205-2208.
-
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clin Infect Dis. 2020 05 23; 70(11):2270-2280.
-
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J Antimicrob Agents. 2019 Dec; 54(6):735-740.
-
Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam. J Antimicrob Chemother. 2019 08 01; 74(8):2466-2467.
-
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019 08 01; 74(8):2464-2466.
-
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019 07 01; 74(7):2051-2054.
-
In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2019 05 01; 74(5):1457-1459.
-
Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect Dis. 2019 Feb 26; 19(1):195.